Materialise 경영진
경영진 기준 점검 2/4
Materialise CEO는 Brigitte de Vet-Veithen, Jan2024 에 임명되었습니다 의 임기는 2.33 년입니다. 는 $159.51K 가치에 해당하는 회사 주식의 0.047% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 11.7 년입니다.
핵심 정보
Brigitte de Vet-Veithen
최고경영자
n/a
총 보수
| CEO 급여 비율 | n/a |
| CEO 재임 기간 | 2.3yrs |
| CEO 지분 보유율 | 0.05% |
| 경영진 평균 재임 기간 | 2.3yrs |
| 이사회 평균 재임 기간 | 11.7yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Apr 29
Materialise: The Medical Segment Alone Makes This A Buy
Summary Materialise receives a 'Buy' rating, driven by robust growth in its medical segment despite weakness in software and manufacturing. MTLS's medical segment boasts a 4-year CAGR of 16%, with management guiding for continued strong growth through FY2026. The company maintains a fortress balance sheet with €71m net cash and trades at a significant discount to sector peers on EV/Sales and EV/EBITDA. My €7.20/share target price reflects medical segment valuation, but risks include potential growth slowdown and further deterioration in non-medical segments. Read the full article on Seeking Alpha분석 기사 • Nov 05
Materialise's (NASDAQ:MTLS) Sluggish Earnings Might Be Just The Beginning Of Its Problems
The market rallied behind Materialise NV's ( NASDAQ:MTLS ) stock, leading do a rise in the share price after its recent...분석 기사 • Oct 06
Materialise NV's (NASDAQ:MTLS) P/E Is On The Mark
With a price-to-earnings (or "P/E") ratio of 54.9x Materialise NV ( NASDAQ:MTLS ) may be sending very bearish signals...분석 기사 • Jul 27
Analyst Estimates: Here's What Brokers Think Of Materialise NV (NASDAQ:MTLS) After Its Second-Quarter Report
Shareholders might have noticed that Materialise NV ( NASDAQ:MTLS ) filed its quarterly result this time last week. The...분석 기사 • Jul 25
Materialise (NASDAQ:MTLS) Is Looking To Continue Growing Its Returns On Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...분석 기사 • May 04
After Leaping 28% Materialise NV (NASDAQ:MTLS) Shares Are Not Flying Under The Radar
Those holding Materialise NV ( NASDAQ:MTLS ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Feb 24
Materialise: Manufacturing Headwinds Are A Distraction
Summary Materialise's share price dropped significantly after the company reported poor Q4 earnings, which were driven by European automotive market weakness. Despite recent challenges, Materialise's Medical segment continues to perform well and the transition of the Software segment to a subscription model is progressing. The Medical and Software segments are Materialise's primary value drivers and more than justify the company's current valuation. Issues with the Manufacturing segment may need to be resolved before the stock moves higher though. Read the full article on Seeking Alpha분석 기사 • Feb 13
Materialise NV's (NASDAQ:MTLS) P/E Is Still On The Mark Following 26% Share Price Bounce
Materialise NV ( NASDAQ:MTLS ) shareholders have had their patience rewarded with a 26% share price jump in the last...
새로운 내러티브 • Feb 09
Launch Of Mimics Flow And ACTech Expansion Will Advance Personalized Medicine
Focus on personalized medical solutions and enhanced platforms could drive revenue growth and improve operational efficiencies and net margins.분석 기사 • Jan 31
Materialise NV (NASDAQ:MTLS) Shares Could Be 28% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Materialise fair value estimate is US$6.77 Materialise is...분석 기사 • Jan 07
These 4 Measures Indicate That Materialise (NASDAQ:MTLS) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Nov 07
Materialise NV's (NASDAQ:MTLS) 27% Jump Shows Its Popularity With Investors
Materialise NV ( NASDAQ:MTLS ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Seeking Alpha • Nov 04
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Summary Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue. Despite the stock moving higher in recent weeks, Materialise remains deeply undervalued. Read the full article on Seeking Alpha분석 기사 • Nov 01
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) recently posted some strong earnings, and the market responded positively. We did some...Seeking Alpha • Oct 25
Materialise: Medical Business Unit Is The Hidden Value
Summary Materialise NV is a Belgian additive manufacturing company, showing a 14.18% CAGR in its Medical segment from FY18 to FY23. Despite mixed results in other segments, Materialise maintains profitability with positive FCF and a strong balance sheet, supported by €63 million in net cash. The company's strategic positioning in high-value sectors and steady growth, combined with a net cash position and positive FCF, highlight its upside potential. DCF analysis suggests Materialise is undervalued by 35-40%, justifying a "buy" rating due to its innovative edge and expanding market in healthcare. Read the full article on Seeking Alpha분석 기사 • Oct 25
Is There Now An Opportunity In Materialise NV (NASDAQ:MTLS)?
While Materialise NV ( NASDAQ:MTLS ) might not have the largest market cap around , it led the NASDAQGS gainers with a...Seeking Alpha • Aug 01
Materialise Stock: Nearing An Inflection Point (Rating Upgrade)
Summary Materialise NV continues to face headwinds from soft prototyping demand and muted 3D printer sales. Despite this, Materialise reported solid Q2 results, with growth improving sharply. Recent acquisitions, new software launches, and expanded manufacturing capacity are expected to drive growth going forward. While Materialise's share price has moved higher recently, the prospect of solid growth and significantly higher margins are not priced into the stock. Read the full article on Seeking Alpha분석 기사 • Aug 01
The Return Trends At Materialise (NASDAQ:MTLS) Look Promising
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Seeking Alpha • Apr 26
Materialise Q1: Progress Against Headwinds
Summary Materialise NV faces a challenging demand environment and is transitioning to a cloud-based SaaS business model, impacting its financial performance. The software business is progressing slowly, while the medical business continues to perform well. The manufacturing business is struggling, but the startup of the expanded ACTech facility later in the year could change this. Macro headwinds and ongoing investments probably limit near-term upside. Longer term, Materialise appears deeply undervalued. Read the full article on Seeking Alpha분석 기사 • Apr 19
Materialise's (NASDAQ:MTLS) Strong Earnings Are Of Good Quality
Materialise NV ( NASDAQ:MTLS ) just reported healthy earnings but the stock price didn't move much. Investors are...Seeking Alpha • Feb 26
Materialise: Upside From A Transition To Profitability
Summary The demand environment continues to weigh on Materialise's business, although the Medical segment remains a standout, with strong growth and improving margins. The adoption of robotics in joint replacement surgeries poses a threat to Materialise's medical business, though. Investments in the CO-AM platform and the ACTech facility expansion should begin to pay off in 2024, supporting growth and Materialise's competitive position. Given Materialise's relatively low valuation and the potential for solid growth and improving margins, Materialise's stock should do well over the next 1-2 years. Read the full article on Seeking Alpha분석 기사 • Feb 23
Does Materialise (NASDAQ:MTLS) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 31
Materialise NV: Consolidation And New Developments To Emerge As A Rising Star In The Additive Manufacturing Industry
Summary Materialise NV currently exhibits better growth, margins and fundamentals than its main competitors, positioning itself well in an industry that is estimated to grow at a CAGR of 16% until 2032; The medical business unit (c.a. 38.5% of total revenues in 9M23) continues to achieve double-digit growth, with the appointment of the new CEO to focus strongly on this segment; Both the analysis of multiples and DCF here presented show that the current share valuation is 40-45% below its fundamental value. Read the full article on Seeking Alpha분석 기사 • Jun 14
Here's Why Materialise (NASDAQ:MTLS) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • May 23
Returns On Capital At Materialise (NASDAQ:MTLS) Paint A Concerning Picture
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...분석 기사 • Mar 14
Health Check: How Prudently Does Materialise (NASDAQ:MTLS) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Nov 22
Materialise (NASDAQ:MTLS) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 30
Materialise: Financials Remain Resilient
Summary Strategic initiatives set Materialise up for long-term growth and should lead to higher margins. How these initiatives will be received by customers remains to be seen though. In the near-term, investments are likely to weigh on margins whilst having little impact on growth. In the current environment this is unlikely to be well received by investors. Materialise is reasonably valued but a deterioration in economic conditions presents a significant downside risk. Materialise (MTLS) was a real narrative stock through the pandemic, with its valuation becoming completely detached from the fundamentals of the business. Despite facing headwinds from a weakening macro environment and high energy prices, Materialise will continue to benefit from secular growth in additive manufacturing and a rebound in automotive and aerospace manufacturing. Given the current valuation, Materialise’s stock should perform well over the long-term, although progress on the profitability front may be required before the stock moves higher. Materialise offers a range of additive manufacturing software as well as on demand parts printing. It segments its business into software, medical and manufacturing. They continue to build out the capabilities of their software platforms and are in the process of shifting towards higher value add manufacturing. CO-AM Platform Materialise will soon be introducing their CO-AM platform, which gives manufacturers cloud-based access to a range of software tools that enable them to plan, manage and optimize every stage of their operations. The CO-AM platform utilizes a datalake to connect all production tools and track operations, which aims to make optimizing operations simpler. Materialise will offer more than 25 software applications on its CO-AM platform, including integration with Magics; AM Watch for shopfloor data collection, and its Build Processors for connectivity with more than 150 different 3D printing systems. Figure 1: CO-AM Platform (source: Materialise) Materialise expects that the CO-AM platform will appeal to customers who operate a larger number of machines, with interest expected to come from something like 20% of the user base. Materialise’s Magics software is already widely used by larger additive manufacturing service organizations for data preparation, potentially giving the company a launchpad from which to introduce a more integrated solution. The CO-AM platform will help to advance the use of additive manufacturing in serial production by helping manufacturers achieve the consistent quality standards that are necessary in mass production. Serial production refers to the manufacturing of large quantities of goods in batches, often producing a range of goods using one machine. For example, serial production would generally be used for mass personalization manufacturing. From a financial perspective, Materialise's software segment is the most attractive part of the business, but growth has stagnated over the past few years. The CO-AM platform could reaccelerate Materialise's software revenue growth, but should also be supportive of its other segments. New Software Products Materialise continue to build on the functionality of their software with the introduction of Magics 26. Magics is software for data and build preparation, and Magics 26 combines support for native CAD workflows with its existing mesh capabilities. Magics 26 will incorporate the Siemens Parasolid kernel, opening up a range of new opportunities for users. Users can make adjustments to the original design files using CAD operations to increase printability. The adjusted file remains compatible with the PLM system and are easiest to use for post-processing steps such as CNC milling operations. Link3D Acquisition Materialise acquired Link3D in 2021 for 33.5 million USD. The acquisition will not have a material impact on revenues in the short-term and will be a drag on margins. In 2021, Link3D had revenues of 2.3 million USD and EBITDA losses of 4.6 million USD. Link3D provides software for digital manufacturing which will help Materialise develop their cloud-based platform, by integrating Link3D’s additive MES (Manufacturing Execution System) solution with Materialise's Magics software suite. MESs track the transformation of inputs into finished products and provide information that allows manufacturing operations to be optimized. Software Materialise sells software that is compatible with nearly all printer types to customers that own 3D printers in order to enhance their efficiency and throughput. Materialise offers two horizontal software platforms, Magics and Mimics. Materialise’s software offerings include: Software that converts a CAD file into a 3D printable format Software to optimize a specific 3D customer application Software to organize and integrate a "factory" of multiple printer types and brands Software revenue comes from software licenses, maintenance contracts and custom software development services with the majority of sales through Materialise's own sales force and a minority through system manufacturers. Medical Materialise produces both custom medical devices and software for making custom devices and helping doctors plan surgeries. 3D printing for medical applications is the fastest growing business at Materialise, driven largely by growing demand for 3D surgical implants. 3D printed medical devices at the moment are primarily surgical guides. In particular, CMF is the growth engine of the medical devices business. The medical business is also fairly exposed to elective surgeries, which was a large headwind early in the pandemic, but had more or less normalized by Q3 2020. Materialise's Mimics Suite realized revenues of almost 23 million Euros in 2021. Materialise is developing AI to support the planning of surgeries and the design of devices, in addition to introducing AR and VR functionality. Manufacturing Materialise utilizes its own printers to manufacture end-use parts and prototypes for customers, primarily in the medical devices and automotive fields. The key differentiating factors of Materialise's 3D printing service are: The size of printers and the prototypes and parts that it can produce via Mammoth stereolithography printers The speed and variety in which parts can be produced, with Materialise operating one of the largest 3D printing sites in the world with a range of printing technologies. Materialise's Manufacturing segment was the most negatively impacted by the pandemic, due in large part to its reliance on the automotive and aerospace sectors. Manufacturing revenue has now fully recovered, with Q2 2022 revenue exceeding Q2 2019 by more than 10%. There has been a substantial shift in the Manufacturing business which has driven this rebound though. The manufacturing business is benefitting from a post-COVID rebound in product development that leverages additive manufacturing for prototyping. Materialise is also doing well in small, certified manufacturing series production. Figure 2: Global Vehicle Production (source: Created by author using data from OICA) Figure 3: Boeing Plus Airbus Revenue (source: Created by author using data from company reports) The importance of the automotive sector to Materialise’s plastics manufacturing activities has declined over time. Industrial goods and medical device contract manufacturing projects grew 25% YoY in Q2 2022, while automotive projects remained stable at 2021’s depressed levels. Within automotive subcontracting, Materialise has instead chosen to focus on areas with better margins, like large stereo-lithography parts printed on their Mammoth printers. ACTech had a large legacy business involved in the development of new internal combustion engines for cars. The combination of diesel gate and the pandemic reduced ACTech’s turnover by approximately 50% in early 2020. ACTech has now pivoted from small cylinder blocks and turbochargers to complex casted components for electric car drive-trains and chassis. This shift has returned ACTech to pre-COVID revenues with a more favorable margin profile. The ACTech facility can now support the manufacture of a wider variety of components and larger components using sand 3D printing. Sand 3D printing uses a sand-like working medium with a polymer to bind the particles together. This can be used to produce finished products or molds for an alternative material to be poured into. This has opened new opportunities for Materialise in agricultural, mining, construction and marine vehicles, producing a small series of large engine parts. The complexity of these types of parts is increasing to improve the thermodynamic efficiency of engines, which necessitates the use of precision sand printing and casting small series parts. Sand printing, molds assembly, metal casting, and post processing steps, like CNC milling, are necessary competencies to support these types of operations, and Materialise believes that offering integrated solutions provides significantly more value to customers. To support this opportunity, Materialise is investing in an additional 9,000 square meter facility that will be dedicated to CNC milling and quality control operations. This facility will also create space for Materialise to increase sand printing, molds assembly and casting operations in the old plant. Materialise expects to invest 23 million Euro’s in the coming years, which will double ACTech’s capacity.분석 기사 • Sep 12
There's Been No Shortage Of Growth Recently For Materialise's (NASDAQ:MTLS) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...분석 기사 • Aug 10
We Think Materialise (NASDAQ:MTLS) Can Manage Its Debt With Ease
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...CEO
Brigitte de Vet-Veithen (53 yo)
2.3yrs
재임 기간
Mrs. Brigitte de Vet-Veithen is Chief Executive Officer of Materialise NV from January 01, 2024 and joined Materialise NV in 2016. Mrs. de Vet-Veithen was Executive Vice President of Materialise Medical of...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder & Chairman | 35.8yrs | 데이터 없음 | 0.28% $ 933.6k | |
| Chief Executive Officer | 2.3yrs | 데이터 없음 | 0.047% $ 159.5k | |
| Chief Financial Officer | 3yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & COO | no data | 데이터 없음 | 0.26% $ 869.7k | |
| Chief Strategy & Technology Officer and Executive VP | 10.3yrs | 데이터 없음 | 0.24% $ 822.6k | |
| Executive Vice President | 26.7yrs | 데이터 없음 | 0.13% $ 428.0k | |
| Interim HR Director & CHRO | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Manufacturing | 2.3yrs | 데이터 없음 | 0.076% $ 259.1k | |
| Executive Vice President of Software | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Medical | 1.3yrs | 데이터 없음 | 데이터 없음 |
2.3yrs
평균 재임 기간
53yo
평균 나이
경험이 풍부한 관리: MTLS의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Founder & Chairman | 35.8yrs | 데이터 없음 | 0.28% $ 933.6k | |
| Independent Director | 8.9yrs | €11.00k | 데이터 없음 | |
| Independent Director | 12.5yrs | €11.00k | 0.31% $ 1.0m | |
| Independent Director | 19.8yrs | €11.00k | 데이터 없음 | |
| Director | 13.3yrs | €11.00k | 0.35% $ 1.2m | |
| Independent Director | 7.5yrs | €11.00k | 0.010% $ 34.4k | |
| Director | 28.4yrs | 데이터 없음 | 0.28% $ 933.6k | |
| Independent Director | 10.9yrs | €11.00k | 0.0049% $ 16.6k | |
| Director | 6.3yrs | €11.00k | 데이터 없음 | |
| Director | 1.3yrs | 데이터 없음 | 데이터 없음 |
11.7yrs
평균 재임 기간
60yo
평균 나이
경험이 풍부한 이사회: MTLS의 이사회는 노련하고 경험이 풍부합니다(평균 재임 11.7 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/13 15:42 |
| 종가 | 2026/05/13 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Materialise NV는 11명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| John Baliotti | Brean Capital Historical (Janney Montgomery) |
| Robert Burleson | Canaccord Genuity |
| Troy Jensen | Cantor Fitzgerald & Co. |